Zobrazeno 1 - 10 of 50 pro vyhledávání: '"Kei Kimizuka"'
1
Akademický článek
Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators
Autor: Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka, Masafumi Kurosumi
Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC). Methods Pa
Externí odkaz: https://doaj.org/article/6f69a6a4de23498b91dd4a4577d0b1f8
Zobrazit plný text záznamu
3
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study
Autor: Yasuo Yamazaki, Kei Kimizuka, Hirofumi Yamada, Takashi Sakurai, Kazushige Futsuhara, Toru Kuroda, Masato Kojima, Sbccsg investigators, Kenichi Inoue, Shigenori Nagai, Satoshi Hata, Tsuyoshi Saito
Publikováno v: Investigational New Drugs
Summary Purpose We examined the feasibility, efficacy, and safety of TS-1 add-on therapy (TAT) in Japanese patients with triple-negative breast caner (TNBC). Methods TAT (TS-1, 80 mg/m2/day, BID, PO), consisting of the 21-day cycles of 14-day consecu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6c8161fcbebeb16bde9c2032057b82a
http://europepmc.org/articles/PMC6985043
Zobrazit plný text záznamu
4
Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)
Autor: Kazushige Futsuhara, Tsuyoshi Saito, Shiori Kaneko, Kenichi Inoue, Satoshi Hata, Satoko Nakano, Takashi Sakurai, Hirofumi Yamada, Masafumi Kurosumi, Kei Kimizuka, Shigenori Nagai
Publikováno v: Journal of Nippon Medical School. 86:165-171
Background Fulvestrant 500 mg has been an option for endocrine therapy for advanced or recurrent breast cancer after prior endocrine treatment since November 2011 in Japan. This study aimed to clarify the effectiveness and safety of fulvestrant 500 m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d473edcd9ebef9f5e991aa9acbedcb3
https://doi.org/10.1272/jnms.jnms.2019_86-305
Zobrazit plný text záznamu
10
A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer
Autor: Shigenori Nagai, Toru Kuroda, Fumio Arisawa, Hiroyuki Ueda, Sbccsg investigators, Kenichi Inoue, Satoshi Hata, Jun Ninomiya, Tsuyoshi Saito, Takashi Sakurai, Hitomi Kodama, Toshihiro Kai, Masafumi Kurosumi, Hirofumi Yamada, Kei Kimizuka, Maki Nakai
Publikováno v: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 84(5)
Objective Combined therapy with bevacizumab and paclitaxel (BP regimen) as a first-line treatment has proven highly effective with good tolerance for patients with metastatic breast cancer (MBC). The objective of this study was to examine the efficac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea66bcb9c663725447b823c1469380a
https://pubmed.ncbi.nlm.nih.gov/29142182
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje